It is plausible that by ARHGEF2 the coordinated activation of specific proteins in the MAPK pathway, may predispose malignant cancer cells to morphological alterations and the acquired invasive behavior that promotes tumor cell dissemination, which are key steps leading to acquiring resistance and driving the NE phenotype. The gene discussed is ARHGEF2; the disease is neoplasm.